Medixall Group Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Medixall Group Inc (CRCX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Medixall Group Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 702,262M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-48.9% annualized vs trailing 12 months), vs holding steady (-1.2%) for its tracked peer group.
- Growth: Medixall Group Inc generated -40.7% revenue growth year over year in Q3 2024, vs 2.5% for its tracked competitors combined.
- Profitability: Its 678.9% net margin compares with 20.9% for the peer group.
- Peer revenue share: Medixall Group Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.01M compares with $0.96M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CRCX Sales vs. its Competitors, Q3 2024
Medixall Group Inc reported revenue contraction of 40.71 % year on year in Q3 2024, below its competitors' combined revenue growth of 2.45 %.
With a net margin of 678.92 %, Medixall Group Inc achieved higher profitability than its competitors (20.87 %).
Medixall Group Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Medixall Group Inc vs. its Competitors, Q3 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Medixall Group Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Medixall Group Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Medixall Group Inc's competitor groups requires a Commercial License.
For context: the Railroads industry grew revenue 6.9% year over year, combined, vs -40.7% for Medixall Group Inc. Medixall Group Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Medixall Group Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Medixall Group Inc | No | Yes | Yes | No |
| Competitors combined (16) | ||||
| Similar Growth & Profitability (8) | 62.50 % (5 of 8) | 62.50 % (5 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CRCX Stock Performance relative to its Competitors
CRCX Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Encore Capital Group Inc | 282.9% | Outperformed |
| 2 | Csx Corporation | 282.9% | Outperformed |
| 3 | General Motors Company | 282.9% | Outperformed |
| 4 | Pra Group Inc | 282.9% | Outperformed |
| 5 | Consumer Portfolio Services Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Medixall Group Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Medixall Group Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Medixall Group Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Medixall Group Inc | - | 0.30 |
| Union Pacific Corp | 162,815.40 | 25,490.00 |
| Csx Corporation | 86,926.84 | 14,512.00 |
| Canadian Pacific Kansas City Ltd | 76,787.38 | 11,664.11 |
| General Motors Company | 73,382.40 | 185,527.00 |
| Norfolk Southern Corp | 70,436.25 | 12,540.00 |
| SUBTOTAL | 607,568.09 | 702,334.99 |
Sign in to see all competitors of Medixall Group Inc .
Sources: Medixall Group Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Medixall Group Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Medixall Group Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Union Pacific Corp | Reportable 98.85 % |
| Csx Corporation | Rail 94.20 % |
| General Motors Company | GM North America 83.10 % |
| Norfolk Southern Corp | Railway Operating Revenues Market Group Merchandise 61.56 % |
| American International Group Inc | North America Operating 30.08 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Medixall Group Inc .
Medixall Group Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Medixall Group Inc | - | 13,232 | -94,048 |
| Union Pacific Corp | 162,815 | 870,352 | 250,282 |
| Csx Corporation | 86,927 | 630,957 | 140,130 |
| Canadian Pacific Kansas City Ltd | 76,787 | 598,804 | 149,766 |
| General Motors Company | 73,382 | 1,189,276 | 13,410 |
| Norfolk Southern Corp | 70,436 | 649,741 | 136,528 |
| PEERS TOTAL | 607,568 | 956,597 | 160,130 |
Sign in to see all peers for Medixall Group Inc .
Medixall Group Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Broadridge Financial Solutions Inc | United States 85.26 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Medixall Group Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 10 companies in Medixall Group Inc's industry classification, broader than the peer set above. Market cap in millions of $.Medixall Group Inc ranks #0 of 10 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,333, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Union Pacific Corp | 162,994 | 36.13 % |
| 2 | Csx Corporation | 86,927 | 19.27 % |
| 3 | Canadian Pacific Kansas City Ltd | 76,947 | 17.06 % |
| 4 | Norfolk Southern Corp | 70,713 | 15.68 % |
| 5 | Westinghouse Air Brake Technologies Corporation | 1,234 | 5.2% |
| 6 | Trinity Industries Inc | 1,234 | 5.2% |
| 7 | The Greenbrier Companies Inc | 1,234 | 5.2% |
| 8 | Ftai Infrastructure Inc | 1,234 | 5.2% |
| 9 | Freightcar America Inc | 1,234 | 5.2% |
| 10 | Rail Vision Ltd | 1,234 | 5.2% |
| 0 | Medixall Group Inc | 42 | 0.00 % |
Market cap and industry share for the rest of Medixall Group Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2016-11-21.
Medixall Group Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Railroads industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (17 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 57.29 % | 54.96 % (avg) | +2.3 pp |
| Operating Margin | -668.06 % | industry median | -691.6 pp |
| EBITDA Margin | -653.00 % | 29.62 % (avg) | -682.6 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 11.51 % (avg) | -11.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Medixall Group Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | -64.64 % | 384.25 % |
| Operating Margin | - | - | - | -125,899.28 % | - | - | -12,917.27 % | -1,398.38 % |
| Return on Invested Capital | 26.89 % | 215.53 % | -753.61 % | -444.65 % | -601.28 % | -679.06 % | 206.19 % | 41.24 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Medixall Group Inc's Strategic Group Map
Every company in Medixall Group Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Medixall Group Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Medixall Group Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 2,333 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 11.51 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Medixall Group Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Medixall Group Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Medixall Group Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Medixall Group Inc falls in the Medium attractiveness / Medium strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Medixall Group Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 16.5 points above the industry aggregate.
Weaknesses
- Operating margin 691.6 points below the industry median.
- Latest-quarter revenue run-rate is decelerating (-48.9% annualized vs trailing 12 months).
Opportunities
- A meaningful share of tracked competitors (31.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Industry dominated by Union Pacific Corp, holding 36.13 % of industry market cap.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Medixall Group Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Medixall Group Inc | 0.01 | 0.01 | - |
| Union Pacific Corp | 0.22 | 0.89 | 1.64 |
| Csx Corporation | - | 0.86 | 1.77 |
| Canadian Pacific Kansas City Ltd | 0.09 | 0.66 | 0.49 |
| General Motors Company | 0.23 | 1.17 | 0.62 |
| Norfolk Southern Corp | 0.38 | 0.86 | 1.08 |
Sign in to see all peers for Medixall Group Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Medixall Group Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Medixall Group Inc | Q3 2024 | -40.7 % | - |
| Union Pacific Corp | Q2 2026 | +12.8 % | +6.2 % |
| Csx Corporation | Q2 2026 | +10.1 % | +20.9 % |
| Canadian Pacific Kansas City Ltd | Q2 2026 | +6.6 % | -21.4 % |
| General Motors Company | Q2 2026 | +1.9 % | -28.5 % |
| Norfolk Southern Corp | Q2 2026 | +11.4 % | -4.6 % |
| PEERS TOTAL | +7.4 % | +59.0 % |
Sign in to see all peers for Medixall Group Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Medixall Group Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Medixall Group Inc | Q3 2024 | -73.8 % | - |
| Union Pacific Corp | Q2 2026 | +62.8 % | -6.7 % |
| Csx Corporation | Q2 2026 | +65.8 % | -25.8 % |
| Canadian Pacific Kansas City Ltd | Q2 2026 | +44.5 % | -7.7 % |
| General Motors Company | Q2 2026 | - | -9.1 % |
| Norfolk Southern Corp | Q2 2026 | +84.9 % | -7.6 % |
Sign in to see all peers for Medixall Group Inc .
Medixall Group Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Medixall Group Inc | - | - | - |
| Union Pacific Corp | 10.50% | 11.20% | 38.65% |
| Csx Corporation | 7.33% | 6.28% | 24.06% |
| Canadian Pacific Kansas City Ltd | 4.41% | 4.64% | 8.10% |
| General Motors Company | 0.74% | 1.10% | 3.22% |
| Norfolk Southern Corp | 5.85% | 6.35% | 16.80% |
Sign in to see all peers for Medixall Group Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Medixall Group Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Medixall Group Inc | - | - |
| Union Pacific Corp | 22.21 | 6.39 |
| Csx Corporation | 27.19 | 5.99 |
| Canadian Pacific Kansas City Ltd | 21.91 | 6.58 |
| General Motors Company | 46.61 | 0.40 |
| Norfolk Southern Corp | 26.73 | 5.62 |
| PEERS AVERAGE | 5.17 | 0.87 |
Sign in to see all peers for Medixall Group Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.